icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
WpJ3CXJyPcqwsaje